Researchers are demonstrating that sequencing the immune repertoire can offer valuable insight into blood cancers, treatment response, and the likelihood of relapse.
NEW YORK (GenomeWeb News) – Sequenta has gained the exclusive rights to iRepertoire's IP related to methods of immune cell sequencing for minimal residual disease testing, the two companies said today.
T-cell receptor sequencing is "a long way from being used clinically," said Robert Holt, head of sequencing at the BC Cancer Agency's Genome Sciences Center and senior author of a recent paper on the subject.
Sequencing the immune repertoire could provide important insights into the nature of disease and infection, and new companies that offer such sequencing and analysis have recently sprung up.
The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.
